Thats not a coincidence
Early results from preclinical and clinical studies have shown the potential benefits of GLP-1RAs in improving glycaemic control, weight management, endothelial function, atherosclerotic plaque stability, systemic inflammation, renal function, BP levels and AF risk
In a cohort of 3731 patients, weight loss of 5%, 10%, and 15% was observed in 63%, 33%, and 14%, respectively, after 56 weeks of treatment (27%, 11%, and 4% with placebo),69 or of an additional 6% at 56 weeks in patients who had already lost 6% through hypocaloric diet and exercise.70 Positive results were also observed in adolescent patients with obesity,71 and in real-life studies substantial weight loss has also been reported.7275 Phase 3 trials with GLP-1 receptor agonists indicated specifically for obesity and overweight
assessment requiring a 100% passing score
Use an insulated cooling case with gel packs or a portable medication cooler designed to maintain 3646F for several hours
2013 Mar Merav Jacobson Bensky, Irit Ayalon-Dangur, Roi Ayalon-Dangur, Eviatar Naamany, Anat Gafter-Gvili, Gideon Koren, Shachaf Shiber